Jing Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing Lin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jiaying Lin
Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications Fenglu Wu
Department of Assisted Reproduction Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China
2 shared publicationsYanwen Zhu
Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
2 shared publicationsBian Wang
Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China
1 shared publication- Jing Zhang
Department of Assisted Reproduction Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China
1 shared publication Kai Zhang
Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin, China
1 shared publication
Latest Publications
Advanced Parental Age and Perinatal Risks in Twins Conceived Through In Vitro Fertilization
Objective: To evaluate the associations between advanced parental age and perinatal risks in twins. Methods: We analyzed 7514 twin pairs conceived through in vitro fertilization. The exposure was advanced parental age (≥ 35 years), analyzed separately for mothers and fathers. Primary outcomes included birth weight discordance, small for gestational age, large for gestational age, macrosomia, low birth weight, very low birth weight, preterm birth, very preterm birth, and extremely preterm birth. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression. Additionally, parental age was analyzed both as a categorical variable and with a restricted cubic spline. The combined effect of advanced age in both parents was further evaluated. Results: Advanced paternal age (≥ 35 years) was associated with increased odds of birth weight discordance (adjusted OR, 1.20; 95% CI, 1.01–1.42). A graded dose‐response association was evident ( p for trend = 0.026), with adjusted ORs for birth weight discordance progressively increasing across paternal age categories: 1.02 (95% CI, 0.83–1.25) for ages 30–34, 1.18 (95% CI, 0.91–1.52) for ages 35–39, and 1.41 (95% CI, 1.02–1.96) for ages ≥ 40 years, all compared to the < 30 years reference group. Restricted cubic spline analysis identified 37 years as a threshold beyond which paternal age significantly elevated birth weight discordance risk. Similarly, advanced maternal age (≥ 35 years) was significantly associated with increased small for gestational age odds (adjusted OR, 1.21; 95% CI, 1.04–1.41), with a significant trend ( p for trend = 0.012) and a restricted cubic spline–derived threshold at 30 years. When both parents were over 35, the odds of birth weight discordance (adjusted OR, 1.37; 95% CI, 1.15–1.63) and small for gestational age (adjusted OR, 1.30; 95% CI, 1.13–1.50) were significantly elevated compared to both being under 35. Conclusions: Advanced parental age was associated with elevated risks of birth weight discordance and small for gestational age in twins, suggesting it as a contributing factor to perinatal risk.
Advanced Parental Age and Perinatal Risks in Twins Conceived Through In Vitro Fertilization
Objective: To evaluate the associations between advanced parental age and perinatal risks in twins. Methods: We analyzed 7514 twin pairs conceived through in vitro fertilization. The exposure was advanced parental age (≥ 35 years), analyzed separately for mothers and fathers. Primary outcomes included birth weight discordance, small for gestational age, large for gestational age, macrosomia, low birth weight, very low birth weight, preterm birth, very preterm birth, and extremely preterm birth. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression. Additionally, parental age was analyzed both as a categorical variable and with a restricted cubic spline. The combined effect of advanced age in both parents was further evaluated. Results: Advanced paternal age (≥ 35 years) was associated with increased odds of birth weight discordance (adjusted OR, 1.20; 95% CI, 1.01–1.42). A graded dose‐response association was evident ( p for trend = 0.026), with adjusted ORs for birth weight discordance progressively increasing across paternal age categories: 1.02 (95% CI, 0.83–1.25) for ages 30–34, 1.18 (95% CI, 0.91–1.52) for ages 35–39, and 1.41 (95% CI, 1.02–1.96) for ages ≥ 40 years, all compared to the < 30 years reference group. Restricted cubic spline analysis identified 37 years as a threshold beyond which paternal age significantly elevated birth weight discordance risk. Similarly, advanced maternal age (≥ 35 years) was significantly associated with increased small for gestational age odds (adjusted OR, 1.21; 95% CI, 1.04–1.41), with a significant trend ( p for trend = 0.012) and a restricted cubic spline–derived threshold at 30 years. When both parents were over 35, the odds of birth weight discordance (adjusted OR, 1.37; 95% CI, 1.15–1.63) and small for gestational age (adjusted OR, 1.30; 95% CI, 1.13–1.50) were significantly elevated compared to both being under 35. Conclusions: Advanced parental age was associated with elevated risks of birth weight discordance and small for gestational age in twins, suggesting it as a contributing factor to perinatal risk.
- Open Access
- 1 July 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 2823-2835
The Efficacy of Letrozole Co-Treatment in an Antagonist Protocol for Women with Polycystic Ovary Syndrome Undergoing IVF: A Retrospective Study
Objective: Our objective was to investigate the efficacy of letrozole co-treatment in an antagonist protocol for infertile women with polycystic ovary syndrome (PCOS). Patients and Methods: This retrospective cohort study included infertile women with PCOS undergoing IVF/ICSI with and without letrozole co-treatment in an antagonist protocol from 2007– 2021 at Shanghai Ninth People’s Hospital (Shanghai, China). A total of 1559 participants were enrolled, with 1227 women in the antagonist group and 332 women in the letrozole co-treatment group. Propensity score-based patient-matching model was conducted to balance covariates between the groups. The primary outcome was the number of retrieved oocytes, with secondary outcomes including endocrine parameters, ovarian stimulation outcomes, pregnancy outcomes, and obstetrical and neonatal complications. Results: Letrozole co-treatment induced significant changes in hormonal regulation, increased the percentage of large follicles, and resulted in fewer retrieved oocytes (P < 0.05). However, there was no negative impact on the number of usable embryos or good-quality embryos (P > 0.05). The live birth rates following fresh embryo transfer were comparable between the letrozole and control groups (single embryo transfer: 28.9% vs 29.7%, P > 0.05; double embryo transfer: 37.3% vs 45.6%, P > 0.05). Additionally, there were no significant differences between the two groups in the live birth rate per patient after frozen embryo transfer and the cumulative live birth rate (P > 0.05). No significant differences in obstetrical and neonatal complications were observed between the groups (P > 0.05). Conclusion: The addition of letrozole to the antagonist protocol for women with PCOS undergoing IVF induces a higher percentage of large follicles during oocyte retrieval, while reducing the overall number of retrieved oocytes. Moreover, the use of letrozole demonstrates comparable clinical outcomes following embryo transfers. These findings highlight the potential application of letrozole in an antagonist protocol for women with PCOS.
- 1 July 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 2823-2835
Open AccessThe Efficacy of Letrozole Co-Treatment in an Antagonist Protocol for Women with Polycystic Ovary Syndrome Undergoing IVF: A Retrospective Study
Objective: Our objective was to investigate the efficacy of letrozole co-treatment in an antagonist protocol for infertile women with polycystic ovary syndrome (PCOS). Patients and Methods: This retrospective cohort study included infertile women with PCOS undergoing IVF/ICSI with and without letrozole co-treatment in an antagonist protocol from 2007– 2021 at Shanghai Ninth People’s Hospital (Shanghai, China). A total of 1559 participants were enrolled, with 1227 women in the antagonist group and 332 women in the letrozole co-treatment group. Propensity score-based patient-matching model was conducted to balance covariates between the groups. The primary outcome was the number of retrieved oocytes, with secondary outcomes including endocrine parameters, ovarian stimulation outcomes, pregnancy outcomes, and obstetrical and neonatal complications. Results: Letrozole co-treatment induced significant changes in hormonal regulation, increased the percentage of large follicles, and resulted in fewer retrieved oocytes (P < 0.05). However, there was no negative impact on the number of usable embryos or good-quality embryos (P > 0.05). The live birth rates following fresh embryo transfer were comparable between the letrozole and control groups (single embryo transfer: 28.9% vs 29.7%, P > 0.05; double embryo transfer: 37.3% vs 45.6%, P > 0.05). Additionally, there were no significant differences between the two groups in the live birth rate per patient after frozen embryo transfer and the cumulative live birth rate (P > 0.05). No significant differences in obstetrical and neonatal complications were observed between the groups (P > 0.05). Conclusion: The addition of letrozole to the antagonist protocol for women with PCOS undergoing IVF induces a higher percentage of large follicles during oocyte retrieval, while reducing the overall number of retrieved oocytes. Moreover, the use of letrozole demonstrates comparable clinical outcomes following embryo transfers. These findings highlight the potential application of letrozole in an antagonist protocol for women with PCOS.
- 14 July 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (10) , 2011-2019
Relationships between birth weight discordance and maternal and perinatal risks among twin pregnancies conceived following frozen embryo transfer
STUDY QUESTION: Is intertwin birth weight discordance associated with adverse maternal and perinatal outcomes following frozen embryo transfer (FET)? SUMMARY ANSWER: For twins conceived following FET, intertwin birth weight discordance is related to elevated risks of neonatal mortality irrespective of chorionicity, and the risk of hypertensive disorders of pregnancy (HDP) is elevated for the mothers of dichorionic twins affected by such birth weight discordance. WHAT IS KNOWN ALREADY: While the relationships between intertwin birth weight discordance and adverse maternal or fetal outcomes have been studied for naturally conceived twins, similarly comprehensive analyses for twins conceived using ART remain to be performed. STUDY DESIGN, SIZE, DURATION: This was a retrospective cohort study of all twin births from 2007 to 2021 at Shanghai Ninth People’s Hospital in Shanghai, China that were conceived following FET (N = 6265). PARTICIPANTS/MATERIALS, SETTING, METHODS: Intertwin birth weight discordance was defined as a 20% difference in neonatal birth weights. The primary study outcome was the incidence of HDP and neonatal death while secondary outcomes included gestational diabetes, placenta previa, placental abruption, intrahepatic cholestasis of pregnancy, preterm premature rupture of the membranes, Cesarean delivery, gestational age, birth weight, stillbirth, birth defect, neonatal jaundice, necrotizing enterocolitis, and pneumonia incidence. Logistic regression models were used to estimate adjusted odds ratios (aORs) and 95% CIs for maternal and neonatal outcomes. Subgroup analyses were conducted, and Kaplan–Meier survival analysis was used to estimate the survival probability. The sensitivity analysis was performed with a propensity score-based patient-matching model, an inverse probability weighting model, a restricted cubic spline analysis, and logistic regression models using other percentage cutoffs for discordance. MAIN RESULTS AND THE ROLE OF CHANCE: Of 6101 females that gave birth to dichorionic twins during the study interval, birth weight discordance was observed in 797 twin pairs (13.1%). In this cohort, intertwin birth weight discordance was related to an elevated risk of HDP (aOR 1.56; 95% CI 1.21–2.00), and this relationship was confirmed through sensitivity analyses. Hypertensive disease risk rose as the severity of this birth weight discordance increased. Discordant birth weight was also linked to increased odds of neonatal mortality (aOR 2.13; 95% CI 1.03–4.09) and this risk also increased with the severity of discordance. Of the 164 women with monochorionic twins, the discordant group exhibited an elevated risk of neonatal death compared to the concordant group (crude OR 9.00; 95% CI 1.02–79.3). LIMITATIONS, REASONS FOR CAUTION: The limitations of this study are its retrospective nature and the fact that the available data could not specify which twins were affected by adverse outcomes. There is a lack of an established reference birth weight for Chinese twins born at a gestational age of 24–41 weeks. WIDER IMPLICATIONS OF THE FINDINGS: These findings suggest that twins exhibiting a birth weight discordance are related to an elevated risk of adverse maternal and perinatal outcomes, emphasizing a potential need for higher levels of antenatal surveillance in these at-risk pregnancies. STUDY FUNDING/COMPETING INTEREST(S): Authors declare no conflict of interest. This study was funded by the Clinical Research Program of Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine (JYLJ202118) and the National Natural Science Foundation of China (Grant Nos 82271693 and 82273634). TRIAL REGISTRATION NUMBER: N/A.
- 14 July 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (10) , 2011-2019
Relationships between birth weight discordance and maternal and perinatal risks among twin pregnancies conceived following frozen embryo transfer
STUDY QUESTION: Is intertwin birth weight discordance associated with adverse maternal and perinatal outcomes following frozen embryo transfer (FET)? SUMMARY ANSWER: For twins conceived following FET, intertwin birth weight discordance is related to elevated risks of neonatal mortality irrespective of chorionicity, and the risk of hypertensive disorders of pregnancy (HDP) is elevated for the mothers of dichorionic twins affected by such birth weight discordance. WHAT IS KNOWN ALREADY: While the relationships between intertwin birth weight discordance and adverse maternal or fetal outcomes have been studied for naturally conceived twins, similarly comprehensive analyses for twins conceived using ART remain to be performed. STUDY DESIGN, SIZE, DURATION: This was a retrospective cohort study of all twin births from 2007 to 2021 at Shanghai Ninth People’s Hospital in Shanghai, China that were conceived following FET (N = 6265). PARTICIPANTS/MATERIALS, SETTING, METHODS: Intertwin birth weight discordance was defined as a 20% difference in neonatal birth weights. The primary study outcome was the incidence of HDP and neonatal death while secondary outcomes included gestational diabetes, placenta previa, placental abruption, intrahepatic cholestasis of pregnancy, preterm premature rupture of the membranes, Cesarean delivery, gestational age, birth weight, stillbirth, birth defect, neonatal jaundice, necrotizing enterocolitis, and pneumonia incidence. Logistic regression models were used to estimate adjusted odds ratios (aORs) and 95% CIs for maternal and neonatal outcomes. Subgroup analyses were conducted, and Kaplan–Meier survival analysis was used to estimate the survival probability. The sensitivity analysis was performed with a propensity score-based patient-matching model, an inverse probability weighting model, a restricted cubic spline analysis, and logistic regression models using other percentage cutoffs for discordance. MAIN RESULTS AND THE ROLE OF CHANCE: Of 6101 females that gave birth to dichorionic twins during the study interval, birth weight discordance was observed in 797 twin pairs (13.1%). In this cohort, intertwin birth weight discordance was related to an elevated risk of HDP (aOR 1.56; 95% CI 1.21–2.00), and this relationship was confirmed through sensitivity analyses. Hypertensive disease risk rose as the severity of this birth weight discordance increased. Discordant birth weight was also linked to increased odds of neonatal mortality (aOR 2.13; 95% CI 1.03–4.09) and this risk also increased with the severity of discordance. Of the 164 women with monochorionic twins, the discordant group exhibited an elevated risk of neonatal death compared to the concordant group (crude OR 9.00; 95% CI 1.02–79.3). LIMITATIONS, REASONS FOR CAUTION: The limitations of this study are its retrospective nature and the fact that the available data could not specify which twins were affected by adverse outcomes. There is a lack of an established reference birth weight for Chinese twins born at a gestational age of 24–41 weeks. WIDER IMPLICATIONS OF THE FINDINGS: These findings suggest that twins exhibiting a birth weight discordance are related to an elevated risk of adverse maternal and perinatal outcomes, emphasizing a potential need for higher levels of antenatal surveillance in these at-risk pregnancies. STUDY FUNDING/COMPETING INTEREST(S): Authors declare no conflict of interest. This study was funded by the Clinical Research Program of Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine (JYLJ202118) and the National Natural Science Foundation of China (Grant Nos 82271693 and 82273634). TRIAL REGISTRATION NUMBER: N/A.